Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years.
Journal: Intestinal research
Published: November 12, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
Journal: Inflammatory bowel diseases
Published: March 03, 2025
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
Journal: Journal of Crohn's & colitis
Published: September 26, 2023
HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients.
Journal: Inflammatory bowel diseases
Published: July 11, 2023
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: January 30, 2023
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Journal: Clinical therapeutics
Published: June 02, 2022
Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis.
Journal: Crohn's & colitis 360
Published: March 23, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Journal: Lancet (London, England)
Published: November 03, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: December 14, 2020
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
Journal: Inflammatory bowel diseases
Published: July 17, 2020
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Journal: Journal of Crohn's & colitis
Published: June 04, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Journal: Gastroenterology
Published: September 12, 2018
Last Updated: 09/26/2026